China's Innovent Biologics signs drug deal with Pfizer worth up to $10.5bn

Nikkei Asia | May 28, 2026, 11:06 p.m. | Original

SHENZHEN -- Chinese biotech firm Innovent Biologics on Friday said it had signed a licensing deal with U.S. pharmaceutical giant Pfizer for cancer drugs worth up to $10.5 billion.

Foxconn to start shipping next-gen transmission tech for AI data centers Kakao strike threat shows South Korea's workers growing bolder on pay